GlassScriptPhysician profile
Sam MD Hajal
NPI 1558450775
$3,479.34
in general payments reported to CMS, 2019-2025
23 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $232 · 2021: $434 · 2022: $216 · 2023: $596 · 2024: $735 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,861 · Education: $17.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,860.51 |
| Education | $17.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $675.77 | 2019-2025 | Lokelma, Farxiga |
| Akebia Therapeutics INC | $492.30 | 2019-2025 | Auryxia, Vafseo |
| Otsuka America Pharmaceutical, INC. | $329.34 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $304.92 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $270.77 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $233.99 | 2019-2025 | Rayaldee |
| Ardelyx, INC. | $212.37 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Vifor Pharma, INC. | $186.29 | 2019-2023 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $124.96 | 2024 | Lupkynis |
| Amgen INC. | $118.44 | 2019-2025 | Tavneos |
| Horizon Therapeutics Plc | $117.73 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $111.47 | 2019-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $51.61 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.88 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $45.83 | 2020-2023 | Ultomiris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $39.40 | 2019 | |
| Ani Pharmaceuticals, INC. | $20.76 | 2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $19.16 | 2025 | Tarpeyo |
| Renalytix Ai, INC. | $17.46 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Novo Nordisk INC | $16.22 | 2021 | |
| Amarin Pharma, INC. | $15.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.13 | 2019 | |
| Mallinckrodt Hospital Products INC. | $13.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Hajal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.